Page 87 - Read Online
P. 87

Page 18 of 22                                                    Ma et al. Hepatoma Res. 2026;12:43





               but also reduces the required number of TACE procedures, thereby mitigating cumulative liver injury and
               overcoming TACE refractoriness; (3) Static to individual evolution: Traditional staging systems evaluate
               patients at a single time point and do not adapt to disease progression or treatment response. Future
               management should incorporate dynamic prediction models that integrate treatment response, longitudinal
               biomarker changes, and real-time clinical data to guide individualized decisions on whether to continue,
               switch, or discontinue TACE. The development of novel embolic materials, such as Zein-based systems [57]
               and magnesium microsphere embolic agents , is expected to enable more precise and durable vascular
                                                      [58]
               occlusion while alleviating post-embolization hypoxia and hepatic function impairment. Moreover, the
               integration of TACE with systemic therapies (such as “TACE + camrelizumab + apatinib”, “TACE +
               durvalumab + tremelimumab”) may further enhance tumor response and reduce the need for repeated
               TACE sessions, thereby preserving liver function and improving survival outcomes. Beyond radiomics and
               circulating biomarkers, pathomics, the high-throughput extraction of quantitative features from digitized
               pathological images, has emerged as a promising avenue for prognosis prediction in HCC patients receiving
               TACE . Pathomics enables the characterization of tumor morphology, cellular architecture, and spatial
                    [59]
               heterogeneity at the histopathological level, complementing the information obtained from medical imaging
               and liquid biopsy . Recent studies have demonstrated that pathomics features, particularly those related to
                             [60]
               tumor-infiltrating lymphocytes and stromal organization, are associated with treatment response and
               survival outcomes in HCC . Furthermore, the integration of pathomics with transcriptomic data (e.g.,
                                      [61]
               transcription factor signatures) has shown potential for predicting TACE refractoriness and characterizing
               the tumor microenvironment. However, it should be noted that pathomics research specifically focused on
               TACE-treated HCC patients remains limited compared with radiomics and genomics. Future studies are
               warranted to establish standardized pathomics workflows and validate their incremental value when
               combined with clinical, radiomic, and circulating biomarker-based models. This multi-dimensional
               integration, encompassing pathomics, radiomics, genomics, and clinical parameters, represents a promising
               direction toward truly individualized prognosis prediction for HCC patients undergoing TACE .
                                                                                                        [59]
               Correspondingly, the future prediction model is no longer a single calculation formula but an intelligent
               system integrating multidimensional data, continuous learning, and dynamic updating. We look forward to
               more prospective multicenter studies to verify the clinical applicability of the new prediction model. At the
               same time, with the transformation of BCLC and other staging systems to the “treatment path” mode, and
               the deep integration of artificial intelligence and real-world data, TACE treatment of HCC is bound to enter
               a new era of more precision, individualization, and dynamic optimization.


               DECLARATIONS
               Acknowledgments
               The Graphical Abstract was created with figdraw.com [Created in figdraw. Ma, Y. (2025) ID:
               AOOOWb4be4].

               Authors’ contributions
               Writing the manuscript, visualization, conceptualization: Ma YY, Chen L, Zhu HD
               Creating and revising the tables and figures: Ma YY, Li CH
               Conceptualization, supervision, project administration, funding acquisition, writing-review and editing: Zhu
               HD, Li YY, Li GJ, Chen L
               All authors read and approved the final manuscript.

               Availability of data and materials
               Not applicable.

               AI and AI-assisted tools statement
               During the preparation of this manuscript, the AI tool DeepSeek (DeepSeek-V3, released 2025-12-26) was
               used solely for language editing and grammar refinement. The tool did not influence the study design, data
               collection, analysis, interpretation, or the scientific content of the work. All authors take full responsibility
   82   83   84   85   86   87   88   89   90   91   92